GSK revealed that the clinical trial of M72/AS01E, a vaccine against pulmonary tuberculosis disease, has reduced new cases in volunteers from Kenya, Zambia, and South Africa. The pharmaceutical company boasted 54 percent efficacy after two years of testing.